Genedata, a leading provider of advanced software solutions for the pharmaceutical, industrial and agro-biotechnology industries, today announced the release of Genedata Selector 4.5. This latest version of the industry’s leading genome knowledge management solution provides new functionality to support precise gene and genome editing by CRISPR/Cas9 and target enrichment sequencing approaches like TLA, SureSelect, and NimbleGen as well as major enhancements for genome sequence quality assessment. Innovative implementations of algorithmic components within the software yield significant performance improvements and deliver unique scalability for the whole genome sequence comparison workflow.
Genedata Selector provides a centralized sequence analysis and data management system for wet-lab personnel, scientists and bioinformaticians to decipher genotype-phenotype relationships and to optimize or develop new cell lines, strains or germplasms. The enhanced genome comparison pipeline can now easily analyze multiple complex eukaryotic genomes resulting in an improved runtime of over 25 fold and thus accelerating data analysis and availability to end-users by the very next day. Further new developments include enhanced interactive analysis and visualization options on the genomic sequence level, including sequence quality scores to support the interpretation of variant data and syntenic regions among the compared genomes.
Advanced annotation and referencing tools enhance the value of proprietary genomes and enable efficient interpretation of biological functions. Intuitive, interactive visualizations support efficient decision making and accelerate the overall process from early investigation to final reporting. Finally, any findings obtained can be instantly shared across the organizations, including raw data, analysis methods and final reports.
Features of Genedata Selector 4.5 include:
“We are very proud of this latest release of Genedata Selector, the first-in-class software solution designed to support efficient genome based applications in biotechnological R&D”, said Dr. Othmar Pfannes, CEO of Genedata. “Genedata Selector will be a key component for the successful integration of innovative technologies like CRISPR/Cas9 and targeted sequencing for gene and genome editing. We are committed to supporting our customers to remain at the forefront of innovation and to improve the efficiency of their research and development projects.”
Genedata transforms life science data into intelligence with a portfolio of advanced software solutions and scientific consulting. With award-winning platforms, combined with deep domain expertise, Genedata enables dramatic increases in productivity and quality of research, development, and production. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, Japan, and the US.
Phone: +41 61 5118 417
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.